Joint Inspections and Parallel Scientific Advice: Same Weaknesses?
This article was originally published in SRA
Executive Summary
The EU and the US regulatory bodies will have to work hard if their planned joint inspections pilot programme is to be more successful than their efforts to provide joint parallel scientific advice, says Fabien Roy.
You may also be interested in...
US FDA And EMA Officials Work To Boost Interest In Parallel Scientific Advice Program
Timeline and predictability concerns aren’t supported by recent data, officials argued, but questions may linger about the eligibility of products with device components.
FDA-EMA Pilot Could Further Push Global Generic Harmonization, But Will Sponsors Use It?
Regulators hope parallel scientific advice pilot for complex generics is more popular than brand program was at start; sponsors want use of foreign comparator products and tighter harmonization.
FDA-EMA Pilot Could Further Push Global Generic Harmonization, But Will Sponsors Use It?
Regulators hope parallel scientific advice pilot for complex generics is more popular than brand program was at start; sponsors want use of foreign comparator products and tighter harmonization.